MN1–Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells
DV Wenge, E Felipe-Fumero, L Angenendt… - Oncogenesis, 2015 - nature.com
Long-term outcome of acute megakaryoblastic leukemia (AMKL) patients without Down's
syndrome remains poor. Founding mutations and chimeric oncogenes characterize various …
syndrome remains poor. Founding mutations and chimeric oncogenes characterize various …
Uncommon cytogenetic abnormalities identifying high-risk acute myeloid leukemia in children
R Masetti, SN Bertuccio, V Guidi, S Cerasi… - Future …, 2020 - Future Medicine
Pediatric acute myeloid leukemia (AML) represents an aggressive disease and is the
leading cause of childhood leukemic mortality. The genomic landscape of pediatric AML has …
leading cause of childhood leukemic mortality. The genomic landscape of pediatric AML has …
Frequent detection of CBFA2T3::GLIS2 fusion and RAM-phenotype in pediatric non-Down syndrome acute megakaryoblastic leukemia: a possible novel relationship …
Y Chen Wongworawat, G Eskandari… - Leukemia & …, 2023 - Taylor & Francis
In 2016, Eidenschink Brodersen et al. from the ChildrenLs Oncology Group (COG) described
a new high-risk subtype of acute myeloid leukemia (AML) with a distinct immunophenotypic …
a new high-risk subtype of acute myeloid leukemia (AML) with a distinct immunophenotypic …
[HTML][HTML] 儿童急性巨核细胞白血病临床特点及预后分析
罗铁梅， 于洁， 安曦洲 - Chinese Journal of Contemporary …, 2021 - ncbi.nlm.nih.gov
儿童急性巨核细胞白血病临床特点及预后分析- PMC Back to Top Skip to main content NIH NLM
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …
Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL …
AL Illert, AK Seitz, C Rummelt, S Kreutmair, RA Engh… - PLoS …, 2014 - journals.plos.org
ABL tyrosine kinase inhibitors (TKI) like Imatinib, Dasatinib and Nilotinib are the gold
standard in conventional treatment of CML. However, the emergence of resistance remains …
standard in conventional treatment of CML. However, the emergence of resistance remains …
NUP98 Rearrangements in AML: Molecular Mechanisms and Clinical Implications
S Mohanty - Onco, 2023 - mdpi.com
Simple Summary NUP98 rearrangements are frequent events in myeloid malignancies,
especially in acute myeloid leukemia (AML). AML patients carrying NUP98 fusions show …
especially in acute myeloid leukemia (AML). AML patients carrying NUP98 fusions show …
[HTML][HTML] Clinical Analysis of Pediatric Acute Megakaryocytic Leukemia With CBFA2T3-GLIS2 Fusion Gene
Y Du, L Yang, S Qi, Z Chen, M Sun, M Wu… - Journal of Pediatric …, 2024 - journals.lww.com
Abstract CBFA2T3-GLIS2 is the most frequent chimeric oncogene identified to date in non–
Down syndrome acute megakaryocytic leukemia (AMKL), which is associated with extremely …
Down syndrome acute megakaryocytic leukemia (AMKL), which is associated with extremely …
Acute myeloid leukemia with RAM immunophenotype: A new underdiagnosed entity
S Gajendra, S Anupurba, R Gupta… - International Journal …, 2023 - Wiley Online Library
Introduction Acute myeloid leukemia (AML) with RAM immunophenotype is a distinct
subtype of AML, as described by the Children's Oncology Group (COG), with characteristic …
subtype of AML, as described by the Children's Oncology Group (COG), with characteristic …
Loss of full-length GATA1 expression in megakaryocytes is a sensitive and specific immunohistochemical marker for the diagnosis of myeloid proliferative disorder …
WY Lee, OK Weinberg, AG Evans… - American journal of …, 2018 - academic.oup.com
Objectives Myeloid proliferative disorders associated with Down syndrome (MPD-DS),
including transient abnormal myelopoiesis and myeloid leukemia associated with Down …
including transient abnormal myelopoiesis and myeloid leukemia associated with Down …
Таргетные препараты в лечении острых миелоидных лейкозов у детей
ГЗ Серегин, АВ Лифшиц, ТТ Валиев - … детской гематологии и …, 2020 - cyberleninka.ru
Возможности современной полихимиотерапии острых миелоидных лейкозов (ОМЛ)
достигли своего предела, позволив получить общую выживаемость у 70% больных …
достигли своего предела, позволив получить общую выживаемость у 70% больных …